Emerging analgesic drugs for Parkinson's disease.
Identifieur interne : 000863 ( PubMed/Corpus ); précédent : 000862; suivant : 000864Emerging analgesic drugs for Parkinson's disease.
Auteurs : Santiago Perez-Lloret ; María Ver Nica Rey ; Estelle Dellapina ; Jean Pellaprat ; Christine Brefel-Courbon ; Olivier RascolSource :
- Expert opinion on emerging drugs [ 1744-7623 ] ; 2012.
English descriptors
- KwdEn :
- MESH :
- chemical , pharmacology : Analgesics.
- chemical , therapeutic use : Analgesics.
- complications : Parkinson Disease.
- drug therapy : Pain, Parkinson Disease.
- etiology : Pain.
- methods : Pain Management.
- Animals, Clinical Trials as Topic, Double-Blind Method, Humans, Randomized Controlled Trials as Topic.
Abstract
Pain affects between 40 and 85% of Parkinson's disease (PD) patients. It is a frequently disabling and overlooked feature, which can significantly reduce health-related quality of life. Unfortunately, there are no universally recommended treatments for this condition.
DOI: 10.1517/14728214.2012.677949
PubMed: 22530847
Links to Exploration step
pubmed:22530847Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Emerging analgesic drugs for Parkinson's disease.</title><author><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name><affiliation><nlm:affiliation>University Hospital and University Paul Sabatier Toulouse 3, Departments of Clinical Pharmacology and Neurosciences, France.</nlm:affiliation></affiliation></author><author><name sortKey="Rey, Maria Ver Nica" sort="Rey, Maria Ver Nica" uniqKey="Rey M" first="María Ver Nica" last="Rey">María Ver Nica Rey</name></author><author><name sortKey="Dellapina, Estelle" sort="Dellapina, Estelle" uniqKey="Dellapina E" first="Estelle" last="Dellapina">Estelle Dellapina</name></author><author><name sortKey="Pellaprat, Jean" sort="Pellaprat, Jean" uniqKey="Pellaprat J" first="Jean" last="Pellaprat">Jean Pellaprat</name></author><author><name sortKey="Brefel Courbon, Christine" sort="Brefel Courbon, Christine" uniqKey="Brefel Courbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22530847</idno><idno type="pmid">22530847</idno><idno type="doi">10.1517/14728214.2012.677949</idno><idno type="wicri:Area/PubMed/Corpus">000863</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000863</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Emerging analgesic drugs for Parkinson's disease.</title><author><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name><affiliation><nlm:affiliation>University Hospital and University Paul Sabatier Toulouse 3, Departments of Clinical Pharmacology and Neurosciences, France.</nlm:affiliation></affiliation></author><author><name sortKey="Rey, Maria Ver Nica" sort="Rey, Maria Ver Nica" uniqKey="Rey M" first="María Ver Nica" last="Rey">María Ver Nica Rey</name></author><author><name sortKey="Dellapina, Estelle" sort="Dellapina, Estelle" uniqKey="Dellapina E" first="Estelle" last="Dellapina">Estelle Dellapina</name></author><author><name sortKey="Pellaprat, Jean" sort="Pellaprat, Jean" uniqKey="Pellaprat J" first="Jean" last="Pellaprat">Jean Pellaprat</name></author><author><name sortKey="Brefel Courbon, Christine" sort="Brefel Courbon, Christine" uniqKey="Brefel Courbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></author></analytic><series><title level="j">Expert opinion on emerging drugs</title><idno type="eISSN">1744-7623</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analgesics (pharmacology)</term><term>Analgesics (therapeutic use)</term><term>Animals</term><term>Clinical Trials as Topic</term><term>Double-Blind Method</term><term>Humans</term><term>Pain (drug therapy)</term><term>Pain (etiology)</term><term>Pain Management (methods)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Randomized Controlled Trials as Topic</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Analgesics</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Analgesics</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Pain</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Pain</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Pain Management</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Clinical Trials as Topic</term><term>Double-Blind Method</term><term>Humans</term><term>Randomized Controlled Trials as Topic</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Pain affects between 40 and 85% of Parkinson's disease (PD) patients. It is a frequently disabling and overlooked feature, which can significantly reduce health-related quality of life. Unfortunately, there are no universally recommended treatments for this condition.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22530847</PMID><DateCreated><Year>2012</Year><Month>05</Month><Day>28</Day></DateCreated><DateCompleted><Year>2012</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1744-7623</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>2</Issue><PubDate><Year>2012</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Expert opinion on emerging drugs</Title><ISOAbbreviation>Expert Opin Emerg Drugs</ISOAbbreviation></Journal><ArticleTitle>Emerging analgesic drugs for Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>157-71</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1517/14728214.2012.677949</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Pain affects between 40 and 85% of Parkinson's disease (PD) patients. It is a frequently disabling and overlooked feature, which can significantly reduce health-related quality of life. Unfortunately, there are no universally recommended treatments for this condition.</AbstractText><AbstractText Label="AREAS COVERED" NlmCategory="METHODS">Evidence about the efficacy and safety of available analgesic treatments is summarized in this review. Potential targets for upcoming therapies are then discussed in light of what is currently known about the physiopathology of pain in PD. Protocols for efficacy and safety assessment of novel analgesic therapies are discussed. Finally, critical aspects of study protocol design such as patient selection or outcomes to be evaluated are discussed.</AbstractText><AbstractText Label="EXPERT OPINION" NlmCategory="CONCLUSIONS">Preliminary results indicate that duloxetine, cranial electrotherapy stimulation, rotigotine, subthalamic or pallidum nuclei stimulation or lesion or levodopa could be effective for treating pain in PD. Similarly, some case reports indicate that repetitive transcranial magnetic stimulation (rTMS) or apomorphine could be effective for relieving painful off-period dystonia. Clinical trials with rTMS or oxycodone/naloxone prolonged-release tablets for neuropathic pain or botulinum toxin for off-period dystonia are underway. Success of clinical trials about analgesic strategies in PD will depend on the selection of the right PD population to be treated, according to the type of pain, and the proper selection of study outcomes and follow-up of international recommendations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perez-Lloret</LastName><ForeName>Santiago</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University Hospital and University Paul Sabatier Toulouse 3, Departments of Clinical Pharmacology and Neurosciences, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rey</LastName><ForeName>María Verónica</ForeName><Initials>MV</Initials></Author><Author ValidYN="Y"><LastName>Dellapina</LastName><ForeName>Estelle</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Pellaprat</LastName><ForeName>Jean</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Brefel-Courbon</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Rascol</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>04</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Opin Emerg Drugs</MedlineTA><NlmUniqueID>101135662</NlmUniqueID><ISSNLinking>1472-8214</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000700">Analgesics</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000700" MajorTopicYN="N">Analgesics</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010146" MajorTopicYN="N">Pain</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059408" MajorTopicYN="N">Pain Management</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22530847</ArticleId><ArticleId IdType="doi">10.1517/14728214.2012.677949</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000863 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000863 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:22530847
|texte= Emerging analgesic drugs for Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:22530847" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |